DK3111950T3 - Fremgangsmåder og sammensætninger relateret til glucocorticoidreceptorantagonisme og prostatacancer - Google Patents
Fremgangsmåder og sammensætninger relateret til glucocorticoidreceptorantagonisme og prostatacancer Download PDFInfo
- Publication number
- DK3111950T3 DK3111950T3 DK16183642.4T DK16183642T DK3111950T3 DK 3111950 T3 DK3111950 T3 DK 3111950T3 DK 16183642 T DK16183642 T DK 16183642T DK 3111950 T3 DK3111950 T3 DK 3111950T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- prostate cancer
- glucocorticoid receptor
- receptor antagonism
- compositions related
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603137P | 2012-02-24 | 2012-02-24 | |
| EP13751132.5A EP2817019A4 (en) | 2012-02-24 | 2013-02-21 | METHODS AND COMPOSITIONS ASSOCIATED WITH GLUCOCORTICOID RECEPTOR ANTAGONISM AND PROSTATE CANCER |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3111950T3 true DK3111950T3 (da) | 2021-10-04 |
Family
ID=49006202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16183642.4T DK3111950T3 (da) | 2012-02-24 | 2013-02-21 | Fremgangsmåder og sammensætninger relateret til glucocorticoidreceptorantagonisme og prostatacancer |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US9289436B2 (da) |
| EP (3) | EP3111950B1 (da) |
| DK (1) | DK3111950T3 (da) |
| ES (1) | ES2888425T3 (da) |
| PL (1) | PL3111950T3 (da) |
| PT (1) | PT3111950T (da) |
| WO (1) | WO2013126581A1 (da) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3111950B1 (en) | 2012-02-24 | 2021-08-25 | The University of Chicago | Methods and compositions related to glucocorticoid receptor antagonism and prostate cancer |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| SG10201912719TA (en) | 2012-09-26 | 2020-02-27 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| EP3079475B1 (en) * | 2013-12-11 | 2020-10-07 | Sloan-kettering Institute For Cancer Research | Glucocorticoid inhibitors for treatment of prostate cancer |
| US20170014391A1 (en) * | 2013-12-11 | 2017-01-19 | Sloan-Kettering Institute For Cancer Research | Sgk1 inhibitors for treatment of prostate cancer |
| US10071130B2 (en) | 2013-12-12 | 2018-09-11 | The University Of Chicago | Methods and compositions related to Hsp90 inhibitors and breast cancer |
| WO2016162229A1 (en) | 2015-04-10 | 2016-10-13 | Capsugel Belgium N.V. | Abiraterone acetate lipid formulations |
| WO2017091574A1 (en) * | 2015-11-25 | 2017-06-01 | Health Research, Inc. | Riluzole and riluzole drug combinations for the treatment of prostate cancer |
| US11124537B2 (en) | 2015-12-23 | 2021-09-21 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| JP6995757B2 (ja) | 2015-12-23 | 2022-01-17 | オリック ファーマシューティカルズ，インク． | グルココルチコイド受容体の阻害剤 |
| US11110103B2 (en) | 2015-12-23 | 2021-09-07 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| GB201609193D0 (en) * | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| WO2017216772A2 (en) * | 2016-06-16 | 2017-12-21 | The University Of Chicago | Methods and compositions for treating breast and prostate cancer |
| CA3034257A1 (en) | 2016-08-29 | 2018-03-08 | California Institute Of Technology | Compositions and methods for treatment of prostate cancer |
| US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| PT3523315T (pt) | 2016-10-07 | 2021-04-29 | Oric Pharmaceuticals Inc | Inibidor de recetor de glucocorticoide |
| KR102035478B1 (ko) * | 2016-10-14 | 2019-10-23 | 제주대학교 산학협력단 | 시클레소나이드를 포함하는, 암 줄기세포 성장 억제용 조성물 |
| AU2018244928B2 (en) | 2017-03-31 | 2023-10-19 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
| EP3641780A4 (en) * | 2017-06-20 | 2021-02-24 | Corcept Therapeutics, Inc. | TREATMENT METHODS OF NEURO-EPITHELIAL TUMORS USING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
| AU2018351714A1 (en) | 2017-10-16 | 2020-04-30 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| EP3480201A1 (en) | 2017-11-06 | 2019-05-08 | Oncostellae, S.L. | New analogs as androgen receptor and glucocorticoid receptor modulators |
| US11299786B2 (en) | 2018-07-05 | 2022-04-12 | Rutgers, The State University Of New Jersey | Gene panel to predict response to androgen deprivation in prostate cancer |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| WO2020132023A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| BR112021015129A2 (pt) | 2019-02-22 | 2021-09-28 | Corcept Therapeutics Incorporated | Método para tratar um paciente que sofre de hipercortisolemia e um sintoma ou comorbidade da mesma |
| JP2023515781A (ja) * | 2020-02-10 | 2023-04-14 | コーセプト セラピューティクス， インコーポレイテッド | 選択的グルココルチコイド受容体モジュレーターを使用して抗腫瘍応答を刺激する方法 |
| EP4244390A1 (en) * | 2020-11-16 | 2023-09-20 | Ambay Immune Sensors and Controls, LLC/Ambay | Compositions and methods for identification, assessment and treatment of cancer patient |
| WO2022133102A1 (en) * | 2020-12-18 | 2022-06-23 | Northwestern University | Pi3k inhibitors for protection against glucocorticoid-induced atrophy |
| US20230302021A1 (en) * | 2022-03-23 | 2023-09-28 | Purdue Research Foundation | Compositions and methods for treating castration-resistant prostate cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005217646A1 (en) * | 2004-02-26 | 2005-09-09 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | A novel cofactor that modulates steroid receptor activities |
| US20120022121A1 (en) | 2007-11-29 | 2012-01-26 | Dalton James T | Indoles, derivatives and analogs thereof and uses therefor |
| US20090156672A1 (en) * | 2007-12-17 | 2009-06-18 | Northwestern University | Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities |
| US8710035B2 (en) | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
| JP5804395B2 (ja) | 2011-02-03 | 2015-11-04 | ポップ テスト オンコロジー エルエルシー | 診断と治療のためのシステムおよび方法 |
| US9314473B2 (en) * | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
| EP3111950B1 (en) | 2012-02-24 | 2021-08-25 | The University of Chicago | Methods and compositions related to glucocorticoid receptor antagonism and prostate cancer |
-
2013
- 2013-02-21 EP EP16183642.4A patent/EP3111950B1/en active Active
- 2013-02-21 US US14/380,606 patent/US9289436B2/en active Active
- 2013-02-21 DK DK16183642.4T patent/DK3111950T3/da active
- 2013-02-21 PL PL16183642T patent/PL3111950T3/pl unknown
- 2013-02-21 WO PCT/US2013/027150 patent/WO2013126581A1/en active Application Filing
- 2013-02-21 PT PT161836424T patent/PT3111950T/pt unknown
- 2013-02-21 ES ES16183642T patent/ES2888425T3/es active Active
- 2013-02-21 EP EP21183080.7A patent/EP3912626A1/en active Pending
- 2013-02-21 EP EP13751132.5A patent/EP2817019A4/en not_active Withdrawn
-
2016
- 2016-02-02 US US15/013,660 patent/US9801893B2/en active Active
-
2017
- 2017-09-14 US US15/704,726 patent/US10300076B2/en active Active
-
2019
- 2019-04-03 US US16/374,157 patent/US10729699B2/en active Active
-
2020
- 2020-06-26 US US16/913,916 patent/US11564932B2/en active Active
-
2022
- 2022-12-23 US US18/088,400 patent/US20230218634A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US9289436B2 (en) | 2016-03-22 |
| US9801893B2 (en) | 2017-10-31 |
| PT3111950T (pt) | 2021-10-19 |
| US11564932B2 (en) | 2023-01-31 |
| US10729699B2 (en) | 2020-08-04 |
| WO2013126581A1 (en) | 2013-08-29 |
| US20190255069A1 (en) | 2019-08-22 |
| US20160151388A1 (en) | 2016-06-02 |
| EP3111950B1 (en) | 2021-08-25 |
| ES2888425T3 (es) | 2022-01-04 |
| EP2817019A1 (en) | 2014-12-31 |
| PL3111950T3 (pl) | 2022-01-17 |
| US20230218634A1 (en) | 2023-07-13 |
| EP3912626A1 (en) | 2021-11-24 |
| US20150010503A1 (en) | 2015-01-08 |
| EP3111950A1 (en) | 2017-01-04 |
| US20200330482A1 (en) | 2020-10-22 |
| US20180036318A1 (en) | 2018-02-08 |
| US10300076B2 (en) | 2019-05-28 |
| EP2817019A4 (en) | 2016-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3111950T3 (da) | Fremgangsmåder og sammensætninger relateret til glucocorticoidreceptorantagonisme og prostatacancer | |
| DK2929031T5 (da) | Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf | |
| DK2877599T3 (da) | Fremgangsmåder og sammensætninger til bestemmelse af resistens overfor androgenreceptorterapi | |
| DK3421051T3 (da) | Fremgangsmåder til glycokonjugering og sammensætninger | |
| HK1214630A1 (zh) | 響應於抗癌療法的腫瘤細胞標誌物 | |
| IL271305B (en) | Anti-ntb–a antibodies and related compositions and methods | |
| EP2895559A4 (en) | BITUMEN COMPOSITIONS AND METHODS OF MAKING | |
| DK2872153T3 (da) | Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf | |
| DK2857401T3 (da) | Hidtil ukendt -lactamaseinhibitor og fremgangsmåde til at fremstille samme | |
| DK2844292T3 (da) | ST2L-antagonister og fremgangsmåder til anvendelse | |
| BR112014020543A8 (pt) | composições de ração e métodos de utilização das mesmas | |
| DK2861223T3 (da) | Sammensætninger og metoder til transmukosal absorption | |
| DK2877019T3 (da) | Sikkerede herbisidiske sammensætninger til anvendelse i ris | |
| DK3301447T3 (da) | Anti-tumorrespons til modificerede selvepitoper | |
| HK1212251A1 (en) | Topical compositions and methods of use | |
| EP3186393A4 (en) | Methods and compositions related to prostate cancer therapeutics | |
| EP2884984A4 (en) | THERAPEUTIC COMPOSITIONS AND METHOD | |
| DK2908661T3 (da) | Mikroalgemelgranulater og fremgangsmåde til fremstilling deraf | |
| SG11201602258WA (en) | Slow-release conjugates of sn-38 | |
| DK2854822T3 (da) | Polysaccharidsammensætninger og fremgangsmåder til anvendelse | |
| DK3175852T3 (da) | Difluorlactamsammensætninger til EP4-medierede osteorelaterede sygdomme og tilstande | |
| IL232466A0 (en) | Preparations and methods for the analysis of prostate cancer | |
| DK2849798T3 (da) | Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder | |
| GB201314485D0 (en) | Materials and methods relating to pancreatic cancer | |
| EP2895186A4 (en) | THERAPEUTIC COMPOSITIONS AND RELATED METHODS |